RT Journal Article
SR Electronic
T1 Evaluating dengue burden in Africa in passive fever surveillance and seroprevalence studies: protocol of field studies of the Dengue Vaccine Initiative
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e017673
DO 10.1136/bmjopen-2017-017673
VO 8
IS 1
A1 Jacqueline Kyungah Lim
A1 Mabel Carabali
A1 Jung-Seok Lee
A1 Kang-Sung Lee
A1 Suk Namkung
A1 Sl-Ki Lim
A1 Valéry Ridde
A1 Jose Fernandes
A1 Bertrand Lell
A1 Sultani Hadley Matendechero
A1 Meral Esen
A1 Esther Andia
A1 Noah Oyembo
A1 Ahmed Barro
A1 Emmanuel Bonnet
A1 Sammy M Njenga
A1 Selidji Todagbe Agnandji
A1 Seydou Yaro
A1 Neal Alexander
A1 In-Kyu Yoon
YR 2018
UL http://bmjopen.bmj.com/content/8/1/e017673.abstract
AB Introduction Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardised methods were launched in three locations in Africa.Methods and analysis In 2014–2017, the Dengue Vaccine Initiative initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon and Mombasa, Kenya to obtain comparable incidence data on dengue and assess its burden through standardised hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys and healthcare utilisation surveys. All three sites conducted case detection using standardised procedures with uniform laboratory assays to diagnose dengue. Healthcare utilisation surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between patients with dengue and non-dengue using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3000 randomly selected residents at each site at 6-month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test.Ethics and dissemination By standardising methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals in 2018.